The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1712-1719

  Meyer zum Buschenfelde C ^a   Metzger, J ^a   Hermann, C ^a   Nicklisch, N ^a   Peschel, C ^a   Bernhard, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GAMMA INTERFERON; GAMMA UROGASTRONE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONE; CELL TRANSFER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0035424915     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1712     Document Type: Article

References (76)

1. + T-helper and a T-killer cell
2. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
3. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
4. Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression
5. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
6. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
7. + T cell responses in antitumor immunity
8. - T cells. Tumor eradication does not require participation of cytotoxic T cells
9. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues
10. + T cells in the antitumor immune response
11. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
12. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells
13. Generation of cytotoxic T-cell responses with synthetic melanoma-associated antigens
14. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
15. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
16. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
17. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
18. + T cell help to elicit protective and therapeutic antitumor immunity
19. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
20. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
21. + T lymphocytes
22. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitope
23. + T lymphocytes of patients with NY-ESO-1-expressing melanoma
24. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
25. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
26. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
27. + T cell adoptive immunotherapy
28. + T cell-dependent tumor eradication in vivo
29. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
30. Cancer tumor antigens
31. The makings of a tumor rejection antigen
32. A new era for cancer immunotherapy based on the genes that encode cancer antigens
33. HER-2/neu oncogenic protein: Issues in vaccine development
34. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
35. Amplification of c-erbB-2 and aggressive human breast tumors?
36. + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
37. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
38. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
39. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
40. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
41. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
42. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
43. + cytotoxic T lymphocytes
44. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer
45. + hematopoietic progenitor cells of the bone marrow and peripheral blood
46. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides
47. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients
48. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
49. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
50. + hemopoietic progenitor cells
51. Cellular immune response to human renal cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTL) clones
52. The gp130-stimulating designer cytokine Hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells
53. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
54. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
55. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
56. + T cells based on cytokine secretion
57. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy
58. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus
59. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
60. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens
61. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
62. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and upregulated by interferon-γ
63. A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17
64. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
65. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
66. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
67. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
68. + Hodgkin's disease
69. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen *0201-restricted cytotoxic T cells in vitro and in vivo
70. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors: Role of stimulator/responder ratio
71. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
72. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
73. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
74. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
75. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
76. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity